Agent Blocks Pain Without Morphine's Side Effects
News Aug 19, 2016
Scientists have synthesized a molecule with a unique profile of highly specific pain-relieving properties and demonstrated its efficacy in mice. Compared to existing opioid pain relievers, like morphine, the new agent, called PZM21, was not “reinforcing” or prone to triggering potentially lethal respiratory impairment – and was also less constipating. Also unlike existing analgesics, it had little effect on spinal cord reflexive responses, instead targeting the brain-mediated emotional/experiential component of pain. In addition to clinical potential, PZM21 also holds promise as a “tool molecule” for exploring the workings of brain pain systems, say the researchers.
The study represents the combined efforts of NIH-funded research teams led by Nobel laureate Brian Kobilka, M.D. , of Stanford University, NIMH-funded Bryan Roth, M.D., Ph.D. (inventor of the chemogenetic technology DREADD), of the University of North Carolina, and Brian Shoichet, Ph.D., of the University of California San Francisco. They report on their findings August 17, 2016 in the journal Nature.
“This work demonstrates the power of structure-based design to speed up the development of drugs with optimal signaling and therapeutic properties,” explained Laurie Nadler, Ph.D., chief of the NIMH Neuropharmacology Program, which co-funded the research along with NIH’s National Institute of General Medical Sciences and National Institute on Drug Abuse.
The researchers achieved PZM21’s specificity by applying knowledge of opioid receptor structure to design an agent optimized for just the desired properties. Evidence suggested that the undesirable side effects of morphine-like opiates work on the receptor through a molecular signaling pathway linked to beta-arrestin, while the desired analgesic effects work through a G protein-coupled receptor pathway. The researchers screened and ranked more than 3 million compounds for these properties – evaluating each in about 1.3 million configurations for their ability to tweak the opioid receptor in the desired ways. After exhaustive winnowing, they used the knowledge gained to synthesize the strongest G protein and weakest beta-arrestin activator. PZM21’s unprecedented chemical structure then performed just as they had theorized in mouse tests of analgesic and side effect potential.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Deadly Mushroom Toxin Helps Fight Cancer?News
The death-cap mushroom has a long history as a tool of murder and suicide, going back to ancient Roman times. While it may seem ill-advised, researchers are eager to synthesize the toxin because studies have shown that it could help fight cancer. Scientists now report how they overcame obstacles to synthesize the death-cap killer compound.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018